Acetylcholinesterase inhibitors improved MMSE scores vs control at 6 months, with a greater effect in Parkinson/Lewy body dementia (2.11 points) than Alzheimer's/vascular dementia (0.91 points).
Meta-Analysis
Do acetylcholinesterase inhibitors and memantine improve MMSE scores in patients with dementia?
AChEIs demonstrate a modest, dementia subtype-dependent improvement in MMSE scores at 6 months, with a smaller effect seen for memantine.
Estimación del efecto: MD 2.11 for PDD/DLB and 0.91 for AD/VD
BACKGROUND: Acetylcholinesterase inhibitors (AChEIs) and memantine are commonly used in the management of dementia. In routine clinical practice, dementia is often monitored via the Mini-Mental State Examination (MMSE). We conducted a systematic review and meta-analysis of the effects of these drugs on MMSE scores. SUMMARY: Eighty trials were identified. Pooled effect estimates were in favour of both AChEIs and memantine at 6 months. Meta-regression indicated that dementia subtype was a moderator of AChEI treatment effect, with the effect of treatment versus control twice as high for patients with Parkinson disease dementia/ dementia with Lewy bodies (2.11 MMSE points at 6 months) as for patients with Alzheimer disease/vascular dementia (0.91 MMSE points at 6 months). Key Messages: AChEIs demonstrate a modest effect versus control on MMSE scores which is moderated by dementia subtype. For memantine the effect is smaller.
Knight et al. (Mon,) conducted a meta-analysis in Dementia. Acetylcholinesterase inhibitors (AChEIs) and memantine vs. Control was evaluated on MMSE scores (MD 2.11 for PDD/DLB and 0.91 for AD/VD). Acetylcholinesterase inhibitors improved MMSE scores vs control at 6 months, with a greater effect in Parkinson/Lewy body dementia (2.11 points) than Alzheimer's/vascular dementia (0.91 points).